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Abstract
Background: Small leucine-rich proteoglycans (SLRPs) play an important role in tissue homeostasis and cell
proliferation since these proteoglycans sequester multiple growth factors. However, the content of SLRPs in
the endometrium of polycystic ovary syndrome (PCOS) women is unknown. Our purpose was to test the
hypothesis that excessive endometrial proliferation in PCOS may be partly related to abnormalities in SLRPs.
Methods: In a cross section study a total of 20 endometrial samples were collected from 10 patients with
PCOS and 10 ovulatory women during their proliferative (pre-ovulatory) phase. The study subjects were matched for
age, body mass index and race. The age range was 20 to 35 years. All volunteers were evaluated in reproductive
endocrinology clinic, Gynecology Division, Clinics Hospital, University of São Paulo Medical School Profile and
concentration of small leucine-rich proteoglycans (decorin, lumican, fibromodulin and biglycan) were determined
by immunohistochemical testing and Western blotting.
Results: Decorin and lumican demonstrated higher immunoreactivity and relative expression in the endometrium of
women with PCOS compared to that of women with regular menstrual cycles.
Conclusion: Our data suggests that the endometrium of PCOS women demonstrate a greater content of SLRP than
controls; decorin and lumican, in particular, were found in higher concentrations in the endometrium of PCOS women
during the proliferative phase. These differences may, in part, explain the excess of endometrial proliferation frequently
observed in PCOS. Further studies are warranted.
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Background
Polycystic ovary syndrome (PCOS) is an endocrine
disorder which affects approximately 5 to 18% of women
in childbearing age depending on the study population
and the diagnostic criteria [1]. The syndrome is associated
with ovulatory dysfunction, which can lead to menstrual
cycle disruption including amenorrhea and oligomenor-
rhea increasing the incidence of infertility [2–4].
Additionally, in most cases PCOS show evidence of insu-
lin resistance and hyperinsulinemia [1].
The incidence of endometrial hyperplasia in PCOS
women is significantly higher than in controls and may,
in part, be the result of hyperestrogenic anovulation and
persistent hyperinsulinemia [5]. However, endometrial
function in women with PCOS appears to differ signifi-
cantly from that of normal endometrium, a difference
that may predispose these patients to endometrial hyper-
plasia and carcinoma [6, 7].
Investigators have reported that in PCOS endometrial
metabolism is altered, with local insulin resistance and
increased growth factor content [8]. Growth factors
mediating inflammation, including cytokines not only
affect endometrial epithelial proliferation, but may alter
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factors in the extracellular matrix (ECM), including the
production and action of small leucine-rich proteoglycans
(SLRPs) [9, 10]. These proteoglycans play an important
role in tissue homeostasis and cell proliferation, and pro-
tect the endometrium against agents that induce excessive
endometrial proliferation [11–14]. Decorin, a specific SLRP,
induces cell cycle arrest by activating cyclin-dependent
protein kinase inhibitor, decreasing the activity and
abundance of multiple cyclins, activating pro-apoptotic
pathways and upregulating p21 synthesis in human
endometrial stromal cells [14, 15].
The increased risk of endometrial hyperplasia and ma-
lignancy in PCOS is believed to be due not only to the re-
duction in the cyclic effect of progesterone, leading to
chronic estrogen exposure, but also to the abnormal pro-
duction of a large number of growth factors, cytokines,
and other elements mediating inflammation [9, 10]. These
factors may alter factors in the ECM, including SRLPs.
However, the content of SLRPs in the endometrium of
PCOS is unknown. Therefore, we designed a pilot study
to test the hypothesis that the content of SLRPs, including
decorin, lumican, fibromodulin, and biglycan, in the endo-
metrium of PCOS subjects is detectable, and abnormal,
which may predispose these patients to the development
of endometrial hyperplasia and malignancy.
Methods
Study subjects
PCOS and control women were recruited from an out-
patient reproductive endocrinology clinic at an academic
tertiary medical care center (Gynecology Division, Clinics
Hospital) from 2013 to 2015. We prospectively recruited
all PCOS subjects first and then a match among controls
was sought (i.e. ±4 kg/m2 in BMI, ±4 years in age, and
similar race to the PCOS subject), either from a previously
recruited pool of controls or, if no control with the needed
parameters was so identified, then a new control was
sought. This recruitment strategy yielded cohorts of PCOS
and controls similar in number, mean BMI, mean age and
race distribution.
PCOS patients
The diagnosis of PCOS was made in accordance with
the Rotterdam 2003 criteria, and subjects were catego-
rized by phenotype (phenotype A-D) [16, 17]. Clinical
hyperandrogenism was established by the presence of
hirsutism, determined by a modified Ferriman and
Gallwey (mFG) score equal to or higher than 8.
Control
Controls were healthy women with confirmed fertility
(having had at least one child previously), who had
undergone tubal ligation and had a long-term history of
menstrual cycles with regular intervals (25–35 days).
These women were not using hormonal contraceptive
methods.
All subjects (PCOS patients and control) were 20–35 years
of age. Women who had causes of hyperandrogenism other
than PCOS, anovulation which had been treated with
hormones or other drugs in the 6 months prior to
the study, systemic diseases, sexually transmitted dis-
eases, uterine tumors, ovarian cysts or tumors, add-
itional endocrine disorders, or using any hormones,
including hormonally active herbal substances, statins,
corticoids, or infertility drugs in the previous 6 months
were excluded.
All participants of the study were subjected to a detailed
history and physical examination, where height, weight,
waist circumference (WC), hip circumference (HC), hir-
sutism by the mFG score, and a transvaginal ultrasound
scan of the ovaries was obtained. Waist circumference was
measured at the narrowest area between the last rib and
the iliac crest, and HC at the most prominent point of the
gluteal area.
This study was approved by the Research Ethics Com-
mittee of the Clinics Hospital, University of São Paulo
School of Medicine (CEP 0164/09) and informed written
consent was obtained from all subjects. The study was
carried out from April 1, 2012 to August 31, 2015.
Endometrial sampling
Endometrial samples (amount was 1.3 ± 0.45 g) were
obtained using the Pipelle de Cornier catheter (Laboratoire
CCD, Paris, France). Participants in the PCOS group were
generally anovulatory and their endometrial biopsies were
performed randomly after a negative pregnancy (β-hCG)
result. Biopsies in the control group were scheduled during
cycle days eight to twelve of the menstrual cycle. The ra-
tionale for this schedule was to avoid the menstruation
period and the periovulatory phase [18].
Histological processing of the endometrial samples
Endometrial samples were fixed for 24 h in 10% formal-
dehyde, dehydrated in increasing concentrations of ethyl
alcohol, cleared in xylene, and then imbedded in paraf-
fin. Paraffin-embedded samples were then cut into ten
3-μm sections per subject. Eight of these sections were
stained for SLRPs by immunohistochemistry (see below),
and the two remaining sections were stained with
hematoxylin and eosin (H&E), to confirm the menstrual
cycle phase (proliferative) using the criteria suggested by
Noyes et al. [19] (Fig. 1).
Sections of endometrium were incubated with the
primary antibody for detection of decorin (Abcam 175,404),
lumican (Abcam 168,348), fibromodulin (Bioss 12,362), and
biglycan (Bioss 7552R), incubated with a second antibody,
namely chicken antirabbit immunoglobulin G (DakoCyto-
mation, Glostrup, Denmark), and then incubated in 0.05%
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DAB (3,3′-diaminobenzidine) (Sigma Chemical Co). Nega-
tive controls were prepared by incubating the sections with
rabbit nonspecific immunoglobulin fraction (DAKOCyto-
mation) instead of the primary antibody and by staining the
sections with hematoxylin for nucleous identification.
The images obtained were examined with optical
microscope and digitally analyzed with the Carl Zeiss®
AxioVision microscopy software (Rel. 4.6. Oberkochen,
Baden-Württemberg).
Tissue homogenate preparation and Western blot analysis
Endometrial samples were homogenized, prepared, and
sonicated in a buffer of 50 mM Tris-HCl, 150 mM NaCl,
and 1% Triton-X pH 7.4 containing a complete protease
inhibitor cocktail and PhosSTOP tablets (Roche Applied
Science). Protein levels were determined by the Bradford
assay and equalized prior to boiling in Laemmli buffer
(Bio-Rad Laboratories, Hercules, CA, USA). To detect
Gal-1 and MAPKs, protein extracts (40 μg per lane) were
loaded onto a 15% SDS-PAGE together with appropriate
molecular weight markers (Bio-Rad Laboratories) and
transferred to ECL Hybond nitrocellulose membranes. Re-
versible protein staining of the membranes with 0.1%
Ponceau-S in 5% acetic acid (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) was performed to verify protein
transfer.
Membranes were incubated for 15 min in 5% BSA in
Tris-buffered saline (TBS) before the addition of the rabbit
polyclonal antibodies anti-decorin (Abcam175404),
anti-lumican (Abcam168348), anti-fibromodulin (Bioss-
12362R), anti-biglycan (Bioss-7552R), and anti-β-actin
(Bs-12362R), all of which were diluted 1:500 in TBS with
0.1% Tween 20 (antibodies were purchased from Santa
Cruz Biotechnology). Incubation was followed by 15 min
of washing with TBS and 60 min of incubation at room
temperature with peroxidase-conjugated goat anti-rabbit
IgG (1:1000; Thermo Fisher Scientific, Inc., Rockford, MI,
USA). Membranes were again washed for 15 min with
TBS. Immunoreactive proteins were detected using an
enhanced Supersignal West Pico chemiluminescent sub-
strate kit (Thermo Fisher Scientific).
After exposure of the blots in dark room the resulting x-
ray film was developed, imaged and quantified using ImageJ
software1.440 (http://imagej.nih.gov/ij/ National Institutes
of Health, Bethesda, MD, USA) to determine the relative
expression (arbitrary units, AU) of SRPL/β-actin.
Hormonal assays
The serum levels of thyroid-stimulating hormone
(TSH), free thyroxine, follicle-stimulating hormone
(FSH), lutein hormone (LH), total testosterone (TT),
free testosterone (Tfree), androstenedione (A), corti-
sol, prolactin (PRL), dehydroepiandrosterone sulfate
(DHEAS), 17α-hydroxyprogesterone (17-OHP), fasting
insulin, fasting glucose, 2-h oral glucose tolerance












Fig. 1 Photomicrographs of the endometrium in the proliferative phase (a, b, and c) of the CONTROL and PCOS women (d, e, and f). Note thicker
surface epithelium (EP) and gland (GL) as well as a higher concentration of leukocytes within the lamina propria of the endometrium of PCOS patients
in d and e compared to a and b (thin arrows). Also note typical apoptosis in d and e (thick arrows) (* mitotic figure). Staining with H.E. d = 200X, b and
e = 400X, and c and f = 100X
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sex hormone-binding globulin (SHBG) were measured
in both groups. Total testosterone levels were determined
in triplicate using an electrochemiluminescence immuno-
assay (Testosterone II Cobas™ kit, Roche Diagnostics
GmbH, Mannheim, Germany). The minimum detectable
level of TT with this assay is 0.025 ng/ml and the main
cross-reaction is with androstenedione (< 2.5%). The intra
assay coefficient of variation (CV) was 12.5% and the inter
assay CV was 13.8%.
Statistical analysis
All measurements were assessed for normality using the
Kolmogorov-Smirnov test. The unpaired Student t-test was
used to compare the PCOS and CONTROL groups. Statis-
tical analysis was performed using the GraphPad Prism soft-
ware version 3.0 for Windows (GraphPad Software, San
Diego, CA, USA). The data are presented as mean ± standard
deviation (SD), and the significance level was set at p < 0.05.
Results
A total of 20 women, aged 20 to 35 years, agreed to par-
ticipate in this pilot study: a) 10 women with PCOS
(PCOS), all phenotype A (hyperandrogenism either clin-
ical and/or biochemical + ovulatory dysfunction + poly-
cystic ovarian morphology), and b) 10 matched controls
(CONTROL). The characteristics of these groups are
depicted in Table 1.
Morphological analysis of endometrial samples
Morphological analysis confirmed that in CONTROL
endometrial tissue obtained was in the proliferative
phase on days 8–12 of the menstrual cycle. Samples
demonstrated a simple columnar epithelium lining and
well-developed glands with cells in mitosis and endo-
metrial stroma with several fibroblasts with an obvious
elliptical nucleus, indicating intense cellular activity and
synthesis of extracellular matrix components (Fig. 1),
which are normal findings in the proliferative phase of
the menstrual cycle in ovulatory patients.
The endometrial tissue of PCOS subjects had the epi-
thelial lining and the glands were thicker, and the endo-
metrial stroma contained many leukocytes, consistent
with excessive estrogenic action compared to CONTROL
subjects [20]. In some PCOS subjects epithelial cells with
signs of apoptosis and well-developed endometrial stroma
were observed (Fig. 1).
Immunohistochemical detection and comparison of SLRPs
in the endometrium
Immunohistochemical analysis demonstrated SLRPs
throughout the ECM of endometrial samples of both
CONTROL and PCOS subjects. In both groups, SLRPs
were also present throughout the endometrial stroma
and could be observed clearly in the basement mem-
brane of blood vessels, the epithelial lining, and the
glands.
In CONTROL the intensity of immunoreactivity of
biglycan and lumican was increased compared to that of
decorin and fibromodulin. Alternatively, in PCOS bigly-
can, decorin, and lumican immunoreactivity were height-
ened compared with that of fibromodulin. Overall, the
immunoreactivity pattern of SRPLs was higher in PCOS
compared to CONTROL subjects (Fig. 2).
Quantification of SLRP expression by Western blotting
The expression of each SRPL studied (i.e. decorin, lumi-
can, fibromodulin, and biglycan) relative to that of β-actin
is summarized in Table 2 and Fig. 3. Overall, decorin and
lumican had higher relative expressions in the PCOS than
in CONTROL subjects (p < 0.05).
Discussion
Endometrial growth and differentiation is under the influ-
ence of sex hormones such as estrogen, progesterone, and
androgens. In women with PCOS there is a deficiency in
cyclic progesterone production due to chronic anovulation
and a relative increase in other substances, such as insulin,
cytokines, and growth factors, which results in an im-
balance in endometrial hemostasis in these patients,
possibly leading to abnormal uterine bleeding, infertil-
ity, and an increased risk of developing endometrial
hyperplasia [3, 21–25]. The specific receptors for insulin
and Insulin Growth Factors (IGFs) as well as high-affinity
IGF-binding proteins (IGFBPs) have been detected in
endometrial tissues [26]. IGFs have proliferative effects
Table 1 Characteristics of participants
CONTROL (n = 10) PCOS (n = 10) p-value
Age, years 28.6 ± 2.0 29.6 ± 1.2 NS
Caucasian, n 5 6 NS
BMI, Kg/m2 27.49 ± 2.45 28.01 ± 3.19 NS
TT (ng/dL) 35.9 ± 11.7 83.09 ± 24.8 < 0.05*
DHEAS (mg/mL) 421.5 ± 52.1 520.4 ± 82.1 NS
TSH (μUI/mL) 2.8 ± 1.7 2.9 ± 1.6 NS
Insulin (μUI/mL) 8.8 ± 2.9 15.5 ± 3.5 < 0.05*
Glucose (mg/dL) 81.8 ± 8.6 89.2 ± 11.9 NS
17-OHP (mg/mL) 17.3 ± 8.4 18.3 ± 7.4 NS
FSH (mUI/ml) 5.0 ± 1.2 5.1 ± 1.1 NS
LH (mUI/ml) 5.9 ± 2.9 9.5 ± 3.8 < 0.05*
PRL (ng/dl) 10.8 (4.3–34.5) 11.4 (4.2–33.5) NS
A (ng/mL) 2.2 ± 0.8 4.2 ± 1.3 < 0.05*
Tfree (pg/dl) 1.7 ± 0.40 2.1 ± 1.0 NS
Data are expressed as median and standard deviation; BMI Body mass index,
TT total testosterone, TSH thyroid stimulating hormone, Tfree free testosterone,
A androstenedione, LH lutein hormone, FSH follicle-stimulating hormone, PRL
prolactin, 17-OHP 17α-hydroxyprogesterone, DHEAS dehydroepiandrosterone
sulfate, NS nonsignificant difference (p > 0.05). *Significance of P-value <0.05
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and the secretion of these IGFBPs, which can modulate
the bioavailability of IGFs by competing with the IGF
receptor, is stimulated by progesterone and inhibited by
insulin. Consequently the action of IGFs may be more in-
tense in endometrial cells [6]. Moreover, both insulin and
IGF-I inhibit the hepatic synthesis of sex-hormone bind-
ing globulin (SHBG) [27], and insulin stimulates aroma-
tase activity in both endometrial glands and stroma, thus
enhancing endogenous endometrial estrogen production
[27, 28]. The final result is an excess of estrogen and IGFs
action on the endometrium of PCOS.
Furthermore, data on stromal (non-epithelial) struc-
tures in the endometrium of women with PCOS are
lacking [3, 10, 24, 25]. Therefore, our pilot study has
contributed to the scientific literature with the following
two findings: a) demonstrating the presence of SLRPs in
the endometrium of women with PCOS; and b) demon-
strating that the SLRP content in these women appears to
be abnormal, specifically appearing to be enhanced
relative to normals.
Previous studies have reported that SRLPs in the endo-
metrium are important for embryonic implantation and
placentation [24, 29, 30]. However, such studies have not
included women with PCOS. In fact, the expression and
distribution of endometrial decorin, biglycan, lumican,
and fibromodulin are hormone dose dependent [30].
The hyperandrogenism may explain the upregulated
production of decorin and lumican. Under the influence
of the ovarian hormones estrogen and progesterone, the
endometrial SLRPs undergo profound changes during
the menstrual cycle in normal women. However, we
have not assayed the level of estrogen and progesterone
at time of endometrial sampling. It is one limitation of
our study.
Increased decorin and lumican in endometrial ECM
may have a local antiproliferative activity due to bind
cytokines and growth factors [31, 32]. Furthermore, some
investigators suggest that decorin and lumican inhibit
tumor growth, particularly in prostate and lung cancer
[33, 34]. Thus, these SLRPs may partially protect the
Fig. 2 Photomicrographs of the endometrium in the proliferative phase of CONTROL and PCOS women. Endometrial fragments subjected
to immunohistochemical methods for identification of decorin, biglycan, lumican, and fibromodulin. Bar = 20 μm
Table 2 SLRP content in endometrial stromal cells in PCOS and CONTROL subjectsa
Anti-decorin Anti-biglycan Anti-lumican Anti-fibromodulin
CONTROL 3.4 ± 0.3** 17.5 ± 5.7 12.1 ± 0.5** 11.9 ± 2.7
PCOS 7.6 ± 0.5 21.1 ± 4.6 40.7 ± 0.4 15.1 ± 3.2
aWestern blotting yield relative to beta-actin values of the SLRPs studied (mean ± SD) in endometrial stromal cells. Data are expressed as median and standard
deviation. ** Significance of P-value <0.05
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endometrium of women with PCOS from malignant
transformation.
The mechanism of action of decorin and lumican
includes blocking tyrosine kinase receptors (TKR) and
reducing the influence of EGFR, IGF-IR, HGFR, and
VEGFR-2 on the endometrium. Moreover, decorin re-
strains angiogenesis by binding to thrombospondin-1,
TGFβ, VEGFR-2, and possibly IGF-IR, and then halting
tumor growth by antagonizing oncogenic TKRs and
angiogenesis [35, 36]. These effects may negatively act
on the implantation process by inhibiting trophoblast
migration and invasion [36].
The collagen fiber is the most abundant component in
the extracellular matrix. It is present in the ECM as a
fibrillar protein providing structural support to cells and
participating in cell-cell and cell-matrix interactions; thus,
it has a fundamental role in tissue architecture [37–39].
Collagen fibers interact with extracellular matrix compo-
nents, such as heparin sulfate. A research carried out by
Giordano et al. [40] demonstrate alterations in the endo-
metrial glycosaminoglycan levels – chiefly those of hepa-
ran sulfate – in women with PCOS.
Conclusion
Notwithstanding the sex steroid disorder, the exact patho-
physiological mechanisms of endometrial PCOS believed
to account for excessive endometrial proliferation are not
known [41, 42]. Our data suggests that the endometrium
of patients with PCOS exhibits higher expressions of dec-
orin and lumican than that of healthy control women in
the proliferative phase of the menstrual cycle. It is then
possible that this proteoglycan excess may interfere with
normal endometrial hemostasis in PCOS. Further studies
are warranted.
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